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Days out of role because of health problems are a major source of lost human capital. We
examined the relative importance of commonly occurring physical and mental disorders in
accounting for days out of role in 24 countries that participated in the World Health Organization
(WHO) World Mental Health (WMH) surveys. Face-to-face interviews were carried out with 62971
respondents (72.0% pooled response rate). Presence of ten chronic physical disorders and nine
mental disorders was assessed for each respondent along with information about the number of
days in the past month each respondent reported being totally unable to work or carry out their
other normal daily activities because of problems with either physical or mental health. Multiple
regression analysis was used to estimate associations of specific conditions and comorbidities
with days out of role, controlling by basic socio-demographics (age, gender, employment status
and country). Overall, 12.8% of respondents had some day totally out of role, with a median of 51.1
a year. The strongest individual-level effects (days out of role per year) were associated with
neurological disorders (17.4), bipolar disorder (17.3) and post-traumatic stress disorder (15.2). The
strongest population-level effect was associated with pain conditions, which accounted for 21.5%
of all days out of role (population attributable risk proportion). The 19 conditions accounted for
62.2% of all days out of role. Common health conditions, including mental disorders, make up a
large proportion of the number of days out of role across a wide range of countries and should be
addressed to substantially increase overall productivity.
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A growing body of research aims to quantify the
societal impacts of physical and mental disorders
on functioning in order to influence social policy
decisions about investing in health care.
1–4 One
important component of this research examines
effects of health problems on days out of role. For
example, these studies have estimated that there are
3.6 billion annual health-related days out of role in
the United States,
5 and that the annual costs of work
loss days due to brain disorders in Europe exceed 178
billion Euros.
6 It is also important to quantify the
relative importance of specific disorders in account-
ing for these effects, and to evaluate the extent to
which expanded outreach and best-practices treat-
ment of the disorders associated with the largest
losses reduce these effects. The first step in such a
program of research should be to distinguish relative
effects of specific disorders. This requires epidemio-
logical data on a broad range of disorders so as to
adjust for the high rates of comorbidity within and
between physical and mental disorders.
7,8 Although
some studies of this sort have been carried out in the
United States,
5,8 we are not aware of any comparable
studies in most other parts of the world.
The current report presents data of this sort from the
World Health Organization (WHO) World Mental
Health (WMH) surveys (www.hcp.med.harvard.edu/
WMH). The WMH initiative was launched by the
WHO to carry out general population surveys in
countries throughout the world to assess the prevalence
and correlates of mental disorders.
9 O n es e c t i o ni nt h e
WMH interviews assesses the presence of commonly
occurring chronic physical disorders in order to
facilitate analysis of the comparative effects of mental
and physical disorders on role functioning. WMH data
from 24 countries are used in this report to examine
these relative effects on days out of role in the month
before interview. A novel method is used to estimate
these effects in such a way as to adjust for comorbidity.
Materials and methods
Samples
A total of 25 WMH surveys were carried out in 24
countries (Table 1). Of these countries, 6 were
classified in 2007 by the World Bank
10 as low- or
lower-middle-income countries (Colombia, India,
Iraq, Nigeria, Peoples’ Republic of China (PRC) and
Ukraine), 6 as upper-middle-income countries
(Brazil, Bulgaria, Lebanon, Mexico Romania, and
South Africa) and 12 as higher-income countries
(Belgium, France, Germany, Israel, Italy, Japan, Neth-
erlands, New Zealand, Northern Ireland, Portugal,
Spain and the United States). All surveys were based
on probability samples of the adult household
population of the participating countries. The sam-
ples were selected either to be nationally representa-
tive (in a majority of countries), representative of all
urbanized areas in the country (Colombia and
Mexico) or representative of particular regions of the
country (Brazil, India, Japan, Nigeria and PRC). More
details about sampling are provided elsewhere.
11
The weighted (by sample size) average response rate
across surveys was 72.0% ranging from 45.9%
(France) to 95.2% (Iraq) (Table 1).
All WMH interviews were administered face to face
by trained lay interviewers using training, and field
quality control procedures described elsewhere.
9,12,13
Informed consent was obtained before beginning
interviews, using procedures approved by the institu-
tional review board of the organization coordinating
the survey in each country. Each interview had two
parts. Part I, which was administered to all respon-
dents, contained assessments of core mental disor-
ders. All Part I respondents who reported a number
of symptoms of any core mental disorder plus a
probability subsample of other Part I respondents
were administered Part II, which assessed correlates
and disorders of secondary interest to the study. The
assessment of physical disorders was included in Part
II. Part II is consequently the focus of the current report.
The Part II data were weighted to adjust for the
undersampling of Part II non-cases and to adjust for
residual discrepancies between sample and population
distributions on a range of socio-demographic and
geographic variables. The total number of Part II
respondents across surveys was 62971, with individual
country sample sizes ranging from 602 (Lebanon) to
7312 (New Zealand).
Measurement
Mental disorders. Mental disorders were assessed
with version 3.0 of the WHO CIDI (Composite
International Diagnostic Interview), a fully struct-
ured lay-administered interview designed to generate
research diagnoses of common mental disorders
according to the definitions and criteria
of both the DSM-IV (Diagnostic and Statistical
Manual of Mental Disorders, 4th Edition) and ICD-
10 (International Classification of Diseases, 10th
Revision) diagnostic systems.
14 The nine mental
disorders considered here include mood disorders
(major depressive disorder and bipolar I-II disorder),
anxiety disorders (panic disorder and/or agoraphobia,
specific phobia, social phobia, generalized anxiety
disorder and post-traumatic stress disorder (PTSD))
and substance disorders (alcohol abuse with and
without dependence and drug abuse with and
without dependence). Only disorders present in the
12 months before interview were considered.
A clinical reappraisal study with blinded clinical
follow-up interviews using the SCID (Structured
Clinical Interview for DSM-IV)
15 in several WMH
surveys (France, Italy, Spain and United States) found
generally good concordance between diagnoses based
on the CIDI and those based on the SCID.
16
Chronic physical disorders. Physical disorders were
assessed with a standard chronic disorder checklist.
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Days out of role due to common conditions
J Alonso et al
1237
Molecular PsychiatryChecklists of this sort have been shown to yield more
complete and accurate reports of disorder prevalence
than estimates derived from responses to open-ended
questions.
17,18 Reports based on such checklists have
been shown in previous methodological studies to
have moderate to good concordance with medical
records.
19,20
The ten conditions considered here were: arthritis,
cancer, cardiovascular disorders (heart attack, heart
disease, hypertension and stroke), chronic pain
conditions (chronic back or neck pain and other
chronic pain), diabetes, migraine or other frequent or
severe headaches, insomnia, neurological disorders
(multiple sclerosis, Parkinson’s and epilepsy or
seizures), digestive disorders (stomach or intestinal
ulcers and irritable bowel disorder) and respiratory
disorders (seasonal allergies, asthma, chronic obstruc-
tive pulmonary disease and emphysema). The symp-
tom-based disorders in this set (arthritis, pain
disorders, heart attack and stroke) were assessed with
respondent reports as to whether or not they ever
experienced the disorder, whereas the remaining
conditions were assessed with respondent reports of
whether or not a doctor or other health professional
ever told them that they had the disorder. Questions
about persistence were also asked about lifetime
Table 2 Sample characteristics by country and country income (The WHO WMH surveys)
Country N Age Females Not
married
High school
or more
Not
working
Mean (s.e.) % (s.e.) % (s.e.) % (s.e.) % (s.e.)
Lower income
Colombia 2381 36.6 (0.4) 54.5 (1.5) 43.4 (1.7) 46.4 (2.1) 46.4 (1.6)
India (Pondicherry) 1373 38.1 (0.6) 50.0 (1.6) 30.2 (2.1) 47.0 (1.9) 52.1 (1.5)
Iraq 4332 36.9 (0.4) 49.7 (1.0) 34.4 (1.2) 35.3 (1.1) 59.2 (1.2)
Nigeria 2143 35.8 (0.4) 51.0 (1.5) 39.7 (1.6) 35.6 (1.3) 31.1 (1.4)
PRC (Beijing, Shanghai) 1628 41.2 (0.6) 47.7 (1.8) 33.4 (1.7) 55.0 (1.6) 41.2 (2.2)
PRC (Shenzhen) 2475 29.1 (0.3) 50.3 (1.6) 46.2 (1.3) 49.4 (1.5) 8.5 (0.6)
Ukraine 1719 46.1 (0.8) 55.1 (1.3) 34.9 (1.4) 81.9 (1.5) 45.6 (2.1)
Middle income
Brazil 2942 39.0 (0.5) 52.8 (1.4) 40.2 (1.6) 47.2 (1.3) 35.4 (1.1)
Bulgaria 2233 47.8 (0.6) 52.2 (1.3) 25.7 (1.6) 64.2 (1.3) 50.4 (1.9)
Lebanon 602 40.3 (0.9) 48.1 (2.6) 39.0 (3.2) 40.5 (2.8) 48.8 (2.4)
Mexico 2362 35.2 (0.3) 52.3 (1.8) 32.7 (1.5) 31.4 (1.6) 41.6 (1.6)
Romania 2357 45.5 (0.4) 52.4 (1.3) 30.4 (1.2) 49.3 (1.7) 60.7 (1.3)
South Africa 4315 37.1 (0.3) 53.6 (1.0) 49.7 (1.1) 37.8 (1.1) 65.1 (1.4)
Higher income
Belgium 1043 46.9 (0.7) 51.7 (2.4) 30.2 (1.7) 69.7 (3.7) 42.2 (1.4)
France 1436 46.3 (0.7) 52.2 (1.8) 29.0 (1.8) — (—) 37.9 (1.8)
Germany 1323 48.2 (0.8) 51.7 (1.4) 36.7 (1.7) 96.4 (0.9) 43.5 (2.1)
Israel 4859 44.4 (0.1) 51.9 (0.2) 32.2 (0.6) 78.3 (0.6) 39.8 (0.7)
Italy 1779 47.7 (0.6) 52.0 (1.5) 33.3 (1.6) 39.4 (1.8) 46.1 (1.7)
Japan 1682 51.2 (0.7) 53.0 (1.9) 31.2 (1.4) 71.6 (1.4) 36.5 (1.8)
Netherlands 1094 45.0 (0.8) 50.9 (2.2) 27.9 (2.6) 69.7 (1.8) 37.7 (2.6)
New Zealand 7312 44.6 (0.4) 52.2 (1.0) 34.8 (1.0) 60.4 (1.0) 31.2 (0.9)
N. Ireland 1708 45.3 (0.6) 51.0 (1.4) 40.4 (1.8) 88.7 (1.0) 37.4 (1.9)
Portugal 2060 46.5 (0.6) 51.9 (1.5) 30.4 (1.4) 54.8 (1.7) 40.3 (1.5)
Spain 2121 45.6 (0.6) 51.4 (1.7) 34.7 (1.5) 41.7 (1.5) 49.6 (1.8)
United States 5692 45.0 (0.4) 53.0 (1.0) 44.1 (1.2) 83.2 (0.9) 33.2 (1.1)
All countries 62971 42.2 (0.1) 51.9 (0.3) 36.6 (0.3) 57.4 (0.3) 42.0 (0.3)
Comparison among
countries
183.8
(<0.0001)
a
1.2 (0.2) 20.3
(<0.0001)
b
165.7 (<0.0001)
b 74.4
(<0.0001)
b
Lower income 16051 37.0 (0.2) 51.1 (0.6) 37.8 (0.6) 47.2 (0.6) 41.8 (0.6)
Middle income 14811 40.3 (0.2) 52.5 (0.6) 38.0 (0.6) 44.5 (0.6) 51.8 (0.6)
Higher income 32109 45.7 (0.2) 52.1 (0.4) 35.2 (0.4) 69.1 (0.4) 37.5 (0.4)
Comparison lower, middle,
higher
655.5
(<0.0001)
a
1.8 (0.2) 10.4
(<0.0001)
b
638.6 (<0.0001)
b 177.6
(<0.0001)
b
Abbreviations: PRC, Peoples’ Republic of China; WHO, World Health Organization; WMH, World Mental Health.
aWald F test (P-value).
bThe w
2 test of independence (P-value).
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Molecular Psychiatrydisorders that can remit. The focus in this report is on
disorders present in the 12 months before interview.
Days out of role. A modified version
21 of the WHO
Disability Assessment Schedule (WHO-DAS)
22,23 was
used to ask respondents the number of days in the 30
days before interview (that is, beginning yesterday
and going back 30 days) they were totally unable
to work or carry out your normal activities because
of problems with either your physical health, your
mental health or your use of alcohol or drugs. Good
concordance of these reports have been documented,
both with payroll records of employed people
24,25 and
with prospective daily diary reports.
26
Statistical analysis
Multiple regression analysis was used to examine
multivariate associations of the physical and mental
disorders assessed in the survey with reported days
out of role in the past 30 days, controlling for age,
gender, employment status and country. As substan-
tial comorbidity was found among the disorders,
27 we
included terms to capture the effects of comorbidity
in the regression models. Given that the number of
possible combinations of comorbid disorders in the
data (2
19 20=524268) far exceeds the number of
respondents, it was necessary to impose some
structure on the terms used to capture the effects of
comorbidity. This was done by including terms for
total number of comorbid disorders and separate
interaction terms for the extent to which the regres-
sion coefficient of each separate disorder changed as a
function of number of comorbid disorders, taking into
account the size of the coefficients associated with the
comorbid disorders. Nonlinear regression methods
requiring iterative estimation procedures
28 were used
for this purpose.
As the outcome variable (a 0–30 measure of number
of days out of role) was highly skewed, we investi-
gated a number of different model specifications that
included an ordinary least squares regression model
and six generalized linear models that considered the
conjunction of two link functions (logarithmic or
square root) and three error structures (constant, error
variance proportional to the mean and error variance
proportional to the mean squared). Standard diag-
nostic procedures to compare model fit
29 showed that
the ordinary least squares model and generalized
linear model with a log link function and constant
variance were the two best-fitting models (detailed
results of model comparison are available on request).
As the prediction equation includes interaction
terms, the predictive effect of each disorder is
distributed across a number of different coefficients.
Simulation was used to produce a single term to
summarize all these component effects. This was
done by estimating the predicted value of the out-
come for each respondent from the coefficients in the
final model (the base estimate) and then repeating
this exercise in a modified form at 19 different times,
each time assuming that one of the 19 disorders no
longer existed. The difference between the predicted
mean of the outcome generated by the simulated
estimate and the base estimate was divided by the
number of respondents with the disorder in question
to obtain the estimated individual-level effect of the
disorder on the outcomes. The estimated societal-
level effect of the disorder was then obtained by
multiplying the individual-level estimate by the
prevalence of the disorder. The same procedure was
used to calculate total effects of any physical disorder,
any mental disorder and any disorder.
Because of the fact that the WMH survey data were
geographically clustered, weighted means, and
design-based methods were needed to obtain accurate
estimates of standard errors and statistical signifi-
cance. The Taylor series linearization method
30
implemented in SAS
31 was used to do this for the
basic model. The more computationally intensive
method of jackknife repeated replications,
30 implemen-
ted in a SAS macro that we wrote for this purpose, was
used to obtain standard errors of the simulated
estimates of individual- and societal-level disorder
effects. Significance tests were consistently evaluated
using 0.05-level, two-sided design-based tests.
More information about the methods used in this
paper can be obtained from the authors on request.
Results
Major demographic characteristics of the sample are
described in Table 2.
The distribution of days out of role
The mean number of health-related days out of role in
the previous month was 1.2 in the total sample, with a
range of 1.0–1.4 across countries in the three income
levels (Table 3). The overall mean can be decomposed
into 12.8% of respondents who reported any days out
of role (14.6% in lower, 10.4% in middle and 13.1%
in higher-income countries) and a mean among those
with any of 9.6 days (8.3 in lower, 9.3 in middle and
10.3 in higher-income countries). The distribution is
skewed to the right, as indicated by the median
among those with any days out of role, 4.2 in the total
sample (4.0 in lower, 4.3 in middle and 4.3 in higher-
income countries) being lower than the mean.
Disorder prevalence estimates
More than half (58.0%) of respondents across coun-
tries reported one or more of the disorders considered
here. The proportion who reported at least one
physical disorder (53.2%) was considerably higher
than the proportion who reported any mental dis-
order (15.4%). The prevalence of having any physical
disorder and any mental disorder both increased
monotonically with country income level: from
45.6% in low/lower-middle to 52.2% in upper-
middle and to 57.4% in high-income countries for
any physical disorder; and from 12.1% in low/lower-
middle to 15.4% for upper-middle and to 17.0% in
high-income countries for any mental disorder. This
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Molecular Psychiatrymonotonic increase existed for 11 of the 19 individual
disorders, with five others either having their lowest
prevalence in low/lower-middle-income countries or
having their highest prevalence in high-income
countries. The three exceptions were headaches and
other chronic pain disorders, both of which had their
highest prevalence in upper-middle-income coun-
tries, and digestive disorders, with highest prevalence
in low/lower-middle-income countries.
The rank order of prevalence estimates across
disorders was very similar in the three groups of
countries, with rank-order correlations across groups
in the range of 0.87–0.97. Chronic pain disorders were
among the two most commonly reported disorders in
all three groups of countries (21.6–23.7%), headaches
among the top two in low/lower-middle- and upper-
middle-income countries (14.5–19.4%) and cardio-
vascular disorders among the top three in upper-
middle- and high-income countries (18.2–18.8%).
Major depression was the most commonly reported
mental disorder in all three groups of countries (4.9–
6.2%), followed by specific phobia (4.2–6.0%). Other
highly prevalent disorders in all groups of countries
were arthritis (12.5–16.6%) and respiratory disorders
(11.9–21.9%).
Respondents who reported any disorder had an
average of 2.1 disorders. Comorbidity was the norm,
with 55.9% of the respondents with a disorder
reporting at least two. Odds ratios (ORs) between
pairs of disorders were largely positive (94.1% of all
the 19 18/2=171 ORs between pairs of disorders)
and statistically significant (90.0% of all ORs). The
ORs were higher (median and interquartile range)
among pairs of physical (2.5, 1.9–3.0) and mental
(7.2, 4.0–8.7) disorders than between physical–mental
pairs (2.0, 1.4–2.6). Similar patterns existed in each of
the three groups of countries (detailed results of all
ORs are available on request).
Mean days out of role per year varied by condition
(Table 4). Individuals with panic (42.9), PTSD (42.7)
and bipolar disorder (41.2) had the highest mean
numbers of days out of role. Trends were similar
across type of countries. Correlations between mean
days out of role across conditions were high in each of
the three income groups (Spearman rank-order corre-
lations in the range 0.62–0.77). PTSD, panic and
generalized anxiety disorder were among the top six
conditions with highest mean days out of role in all
three income groups. Individuals with any disorder
had an average of 24.2 more days out of role in a year
(31.1 days those with any mental, 24.5 those with any
physical) than those with no conditions.
Table 5 shows the additional days totally out of
role in a year among respondents with a disorder
(individual-level effect), adjusting by age, gender,
marital status and employment as well as the number
and type of comorbid disorders. The most disabling
conditions were bipolar disorder (36.5 additional
days), neurological disorders (33.7) and panic (24.3)
in lower-income countries, generalized anxiety dis-
order (24.6 additional days), bipolar (23.4), neurolo-
gical (18.6) and panic (17.6) in middle-income
countries and pain (19.6 additional days), digestive
(16.6) and PTSD (16.2) in higher-income countries.
Rank correlations of individual effects of the condi-
tions were low across country type (from 0.12 to 0.26).
Interactions were found to be sub-additive for most
disorders in all three income groups: the incremental
Table 3 Distribution of days totally out of role, by type of country (The WHO WMH surveys)
Low income Medium income High income All countries Tests
% s.e. % s.e. % s.e. % s.e. w
2 P-value d.f.
Any days out of role 14.6 0.4 10.4 0.4 13.1 0.3 12.8 0.2 29.8 <0.001 2
1 day 13.5 0.9 12.5 1.2 17.8 0.9 15.6 0.6
2 days 18.4 1.0 17.0 1.2 15.8 0.7 16.8 0.5
3–5 days 29.4 1.2 29.6 1.6 22.2 0.9 25.7 0.7
6–10 days 17.1 1.1 14.3 1.0 13.2 0.7 14.5 0.5
11–20 days 8.1 0.8 10.6 0.9 9.1 0.5 9.1 0.4
21–30 days 13.5 1.0 16.1 1.2 21.9 0.8 18.3 0.6 81.2
a <0.001 10
Mean s.e. Mean s.e. Mean s.e. Mean s.e. w
2 P-value d.f.
Mean days out of role per
month (all respondents)
1.2 0.1 1.0 0.1 1.4 0.0 1.2 0.0 35.1 <0.001 2
Mean days out of role per
month (respondents with
any day out of role)
8.3 0.3 9.3 0.3 10.3 0.2 9.6 0.2 29.7 <0.001 2
Median days out of role
per month (respondents
with any day out of role)
4.0 0.2 4.3 0.1 4.3 0.0 4.2 0.0
Abbreviations: WHO, World Health Organization; WMH, World Mental Health.
aTest for difference between distributions of days out of role (among respondents with any) across income groups.
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Figure 1 Yearly days totally out of role because of each of the 19 health conditions considered: (a) Among those suffering
from the condition (‘individual effect’); and (b) population attributable risk proportion (PARP). All countries: WHO World
Mental Health surveys.
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Molecular Psychiatryincrease in days out of role is smaller when a disorder
occurs comorbidly compared with when the same
disorder occurs in isolation (results are not shown but
available on request).
In Table 5, the population attributable risk propor-
tion (PARP) of days totally out of role for each
condition is also presented. Pain disorders contribute
the highest proportion (21.5% on average), followed
by headache/migraine (6.9%), cardiovascular (6.3%)
and depression (5.1%). For each condition, PARPs
tended to be fairly similar across country types,
especially between lower- and middle-income coun-
tries (Spearman correlations 0.32).
Individual effects and PARPs for all countries
combined are presented in Figure 1. The figure clearly
shows that the most impacting disorders according to
their individual-level effect—most notably neurologi-
cal, bipolar and pain disorders—(Figure 1a) are quite
different from those that have the most impact at the
societal level—pain, cardiovascular and depression
(Figure 1b).
Discussion
A number of limitations must be considered before
interpreting our results. First, only a restricted set of
the most common conditions was included in the
analysis and some were pooled to form larger disorder
groups. Some burdensome conditions, such as de-
mentia and psychosis, were not included. Although
the conditions that we did consider and include were
among those most commonly reported in previous
population studies,
5 an expansion and disaggregation
of these conditions is clearly needed in future studies.
Second, diagnoses of chronic physical conditions
were based on self-reports. Prior research has demon-
strated reasonable correspondence between self-re-
ported chronic conditions such as diabetes, heart
disease and asthma, and general practitioner re-
cords,
32 but some bias might account for the generally
higher prevalence estimates of these conditions in
developed than developing countries. Likely, higher
rates of medical treatment and detection in developed
countries artificially inflate prevalence country differ-
ences. Third, we only considered the days out of role
that the respondents reported they were totally unable
to do their work or usual activities. It is common that
individuals perform their role activities less or worse
than expected (for example, presenteeism);
33 there-
fore, information about days out of role underesti-
mates total productivity loss. Finally, to increase
validity of self-reporting, we assessed restriction of
activities in the 30 days previous to the interview and
then projected the numbers in this recall interval to
the whole year, improving the comparability with
published literature.
5 But some mismatch between
severity of the disease and its prevalence may exist;
for more episodic conditions, this recall period might
have missed a severe exacerbation present in the
previous year but not in the month before the
interview. Because of the relative large number of
events assessed, we expect this to cancel out with
the opposite situation and overall not affect our
estimates.
Within the context of these limitations, we identi-
fied a number of disorders that cause a great deal of
disability. For the overall sample (Table 4), sufferers
of bipolar disorder, PTSD and panic disorder have the
highest disability, followed closely by those with
generalized anxiety disorder and social phobia. These
results show that mental disorders are among the
most strongly associated with productivity loss. This
finding is broadly consistent with previous studies.
34
Nevertheless, as comorbidity is so frequent, and
especially so for mental disorders, the observed
associations in previous studies, which failed to
adjust adequately for comorbidity, could have been
due not to the particular conditions themselves, but
to their high comorbidity. This possibility was
addressed in the analysis reported here by controlling
for comorbidity. In Table 5 (individual effect), we
observe that the rank ordering of disorders in terms of
relative impacts on days out of role change when we
adjust for comorbidity. It is consequently important to
consider comorbidity in assessing the relative effects
of particular disorders on days out of role.
Our results show that the 19 health conditions
considered in our study account for almost two-thirds
of all days of role in the general populations of the
countries studied (PARP=62.2%). Physical condi-
tions accounted for 47.6% and mental disorders for
16.5%. It should be noted that the physical conditions
include neurological disorders (epilepsy, multiple
sclerosis and stroke), pain conditions (including
severe headache/migraine) and insomnia. If insomnia
was considered a mental disorder instead of a
physical disorder, mental disorders would account
for up to 20.3% of days out of role (data not shown,
but available from the authors). Pain conditions are
disabling and highly prevalent and they are, by far,
the most important contributor to days totally out of
role in the population. Also, cardiovascular disorders,
depression and migraine are major contributors to
population-level days out of role. These conditions
should be prioritized in trying to improve the
productivity of our societies. Nonetheless, although
PARPs indicate the theoretical proportion of outcome
events that could be avoided if the exposure
(the disorders in our study) was completely elimi-
nated, and are useful for identifying the burden-
some targets for population intervention, it should
be borne in mind that disability days avoided by
removing one disorder might limit the opportunity
of avoiding the same days by removing another
condition.
35
With a few exceptions, the results presented in this
study are similar across the type of countries studied.
We had anticipated that cultural, social and economic
differences could modulate the association of dis-
orders with days out of role. First, the differences
across type of countries in the average proportion of
individuals reporting days they were totally unable to
Days out of role due to common conditions
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Molecular Psychiatrycarry out normal activities were small. Nevertheless,
the mean number of yearly days lost among those
with days out of role tended to vary more across type
of country. These differences might be because of not
only a higher prevalence of disorders, but also a more
developed welfare system in higher income countries.
Some country differences, nevertheless, deserve
further research.
Implications
A first implication is the identification of the relative
contribution of different common disorders to the
population loss of productivity. Lowering the impact
of common and disabling conditions, such as pain,
migraine, as well as cardiovascular and depression,
would have major productivity returns. If we take
into account that indirect costs are usually higher
than direct medical and social services costs to care
for disorders,
6,36,37 prevention and treatment of these
disorders may be cost effective.
Another implication is that interactions were found
to be sub-additive in the best-fitting model. This does
not mean that comorbidity is not highly disabling.
On the contrary, there is clear evidence of its high
burden.
38 But it does mean that disability increases at
a decreasing rate when comorbid conditions exist.
This finding has an important implication for the
prevention of disability: addressing only one disorder
(treatment or prevention) when it coexists with other
disorders will render a less effective outcome than
addressing all the coexisting conditions.
39
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